Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
AssigneeJanssen Pharmaceuticals, Inc.
InventorsTim Hugo Maria JONCKERS, Frederik PAUWELS, Yannick DEBING
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.
Claims26
A method of treating a hepatitis E virus (BEV) infection in a subject in need thereof, comprising administering to the subject a compound that is:
A pharmaceutical composition for treating a hepatitis E virus infection in a subject in need thereof, comprising a compound that is:
- and a pharmaceutically acceptable vehicle.
A pharmaceutical composition for treating a hepatitis E virus infection in a subject in need thereof, comprising a compound that is:
- and a pharmaceutically acceptable vehicle.
A method for treating a hepatitis E virus (HEV) infection in a subject in need thereof, comprising administering a compound of formula (I) to the subject:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- Base is (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) or (b-8):
- R1 is OH or F;
- G1 is absent, (g-1), (g-2), or (g-3):
- wherein:
- ‘’ is a bond when G1 is (g-1), (g-2), or (g-3);
- and ‘--’ is absent when G1 is absent;
- R8 is C1-4alkyl or C3-6cycloalkyl;
- R9 is C1-4alkyl;
- R10 is C2-3alkenyl or C3-6cycloalkyl;
- wherein:
- (i) when G1 is absent, R2 is OH;
- (ii) when G1 is (g-1), (g-2), or (g-3), R2 is —O—;
- (iii) when G1 is (g-1), (g-2), or (g-3), R3 is —O—;
- (iv) when G1 is present, R2 is O;
- R3 is O;
- and R4 is H and F;
- and
- (v) when G1 is absent, R3 is (f-1), (f-2) or (f-3):
- wherein:
- R5 is C1-4alkyl or C3-6cycloalkyl;
- R6 is C1-4alkyl or C3-6cycloalkyl;
- and
- R7 is C1-4alkyl.
Dependencies are inferred from the claim text.